Sign in

You're signed outSign in or to get full access.

Mani Furuhar

Managing Director and Senior Research Analyst at Leerink Partners

Mani Foroohar, M.D., is a Managing Director and Senior Research Analyst at Leerink Partners specializing in Genetic Medicines within the Therapeutics team. He covers a targeted list of biotech companies, including BridgeBio Pharma and 4D Molecular Therapeutics, achieving an average stock price target met ratio of 57.25% and a documented potential upside of 44.81% across 409 ratings on 27 stocks; his best-performing recommendation generated an 11.19% return in one day on 4D Molecular Therapeutics. Foroohar joined Leerink Partners in 2018 following analyst roles at Aptigon Capital (Citadel), Green Owl Capital Management, and Barclays, and co-founded Cellanyx Diagnostics. He holds an M.D. from Stanford, an M.B.A from Columbia, a B.S. from UCLA, has been a Howard Hughes Medical Institute Research Fellow, and is a FINRA-registered securities professional.

Mani Furuhar's questions to ARROWHEAD PHARMACEUTICALS (ARWR) leadership

Question · Q3 2025

Mani Furuhar's representative asked about the upcoming ARO-INHBE obesity data, specifically which cohorts would be included and what the company hopes to see relative to other muscle-sparing agents.

Answer

Management confirmed that data from single-ascending dose, multiple-ascending dose, and combination cohorts will be presented. The data will include various biomarkers, body composition changes measured by MRI, weight loss, and effects on lipid and glycemic parameters.

Ask follow-up questions

Fintool

Fintool can predict ARROWHEAD PHARMACEUTICALS logo ARWR's earnings beat/miss a week before the call